New hope against Drug-Resistant TB: phase II trial launches
NCT ID NCT07393438
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding acetohydroxamic acid (AHA) to a short-course antibiotic regimen can safely and effectively treat multidrug-resistant tuberculosis (MDR-TB). About 120 adults with confirmed MDR-TB will receive either AHA or a placebo alongside standard drugs. The goal is to find the best dose and see if the combination clears the bacteria from sputum faster.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MDR-TB are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Anhui Chest Hospital
Hefei, Anhui, 230000, China
-
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, 200433, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New 6-Month drug cocktail aims to tame resistant TB
- New hope for kids with Drug-Resistant TB: delamanid studied in children
- Scientists probe immune secrets of tuberculosis to find better treatments
- Sputum DNA test aims to outsmart Drug-Resistant TB
- New hope for kids with Drug-Resistant TB: pretomanid dose study completed
- New 6-Month TB drug cocktail could replace Year-Long ordeal